Dashboard
Manage Tickers

AMGN AMGEN INC

Nasdaq amgen.com


$ 292.38 $ 0.82 (0.28 %)    

Monday, 13-Oct-2025 15:59:58 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 601.73 $ 2.18 (0.36 %)
DIA $ 460.73 $ 2.46 (0.54 %)
SPY $ 662.84 $ 2.37 (0.36 %)
TLT $ 90.57 $ 0.29 (0.32 %)
GLD $ 378.05 $ 1.62 (0.43 %)
$ 290.13
$ 290.86
$ 291.00 x 5
$ 295.89 x 1
$ 290.86 - $ 296.01
$ 247.06 - $ 330.26
2,660,454
na
156.19B
$ 0.48
$ 23.60
TBD
na
na ($ 0.03)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-05-2025 06-30-2025 10-Q
2 05-01-2025 03-31-2025 10-Q
3 02-14-2025 12-31-2024 10-K
4 10-30-2024 09-30-2024 10-Q
5 08-06-2024 06-30-2024 10-Q
6 05-02-2024 03-31-2024 10-Q
7 02-14-2024 12-31-2023 10-K
8 10-31-2023 09-30-2023 10-Q
9 08-03-2023 06-30-2023 10-Q
10 04-28-2023 03-31-2023 10-Q
11 02-09-2023 12-31-2022 10-K
12 11-04-2022 09-30-2022 10-Q
13 08-04-2022 06-30-2022 10-Q
14 04-28-2022 03-31-2022 10-Q
15 02-16-2022 12-31-2021 10-K
16 11-03-2021 09-30-2021 10-Q
17 08-03-2021 06-30-2021 10-Q
18 04-28-2021 03-31-2021 10-Q
19 02-09-2021 12-31-2020 10-K
20 10-29-2020 09-30-2020 10-Q
21 07-29-2020 06-30-2020 10-Q
22 05-01-2020 03-31-2020 10-Q
23 02-12-2020 12-31-2019 10-K
24 10-30-2019 09-30-2019 10-Q
25 07-31-2019 06-30-2019 10-Q
26 05-01-2019 03-31-2019 10-Q
27 02-13-2019 12-31-2018 10-K
28 10-31-2018 09-30-2018 10-Q
29 07-27-2018 06-30-2018 10-Q
30 04-25-2018 03-31-2018 10-Q
31 02-13-2018 12-31-2017 10-K
32 10-26-2017 09-30-2017 10-Q
33 07-26-2017 06-30-2017 10-Q
34 04-27-2017 03-31-2017 10-Q
35 02-14-2017 12-31-2016 10-K
36 10-28-2016 09-30-2016 10-Q
37 07-29-2016 06-30-2016 10-Q
38 05-02-2016 03-31-2016 10-Q
39 02-16-2016 12-31-2015 10-K
40 11-02-2015 09-30-2015 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

trump-plans-astrazeneca-deal-to-cut-drug-prices-for-low-income-americans
Trump Plans AstraZeneca Deal To Cut Drug P...
10/10/2025 18:48:27

Trump to announce new deal with AstraZeneca to lower prescription drug costs for Americans using most-favored-nation pricing mo...

trump-administration-engages-pharmacies-goodrx-for-trumprx-launch
Trump Administration Engages Pharmacies, G...
10/09/2025 19:09:34

Pharmacies and GoodRx are in talks to join TrumpRx, a new drug pricing site aiming to lower prescription costs for U.S. consumers.

Core News & Articles
10 Health Care Stocks Whale Activity In To...
10/08/2025 17:35:32

amgen-to-offer-cholesterol-drug-at-60-discount-as-trump-administrations-call-to-lower-drug-prices
Amgen To Offer Cholesterol Drug At 60% Dis...
10/06/2025 18:27:22

Amgen launches AmgenNow, offering Repatha at $239 per month, expanding direct access for U.S. patients with no insurer restrict...

Core News & Articles
GoodRx And Amgen Partner To Offer Repatha ...
10/06/2025 13:16:21

The collaboration with Amgen reduces out-of-pocket costs for patients and expands access to an innovative cholesterol-lowering ...

amgen-launches-amgennow-program-offering-repatha-direct-to-patients-at-239month-nearly-60-below-list-price
Amgen Launches AmgenNow Program, Offering ...
10/06/2025 13:08:09

Eligible Patients Can Access Repatha at Nearly 60% Discount From the List Price THOUSAND OAKS, Calif., Oct. 6, 2025 /PRNewswire...

wall-street-hits-record-highs-as-rate-cut-bets-offset-shutdown-this-week-in-markets
Wall Street Hits Record Highs As Rate Cut ...
10/03/2025 20:15:46

S&P500, Nasdaq100, Dow Jones, and Russell 2000 all hit record highs as investors focus on corporate optimism, monetary easi...

pe-ratio-insights-for-amgen
P/E Ratio Insights for Amgen
10/03/2025 19:00:44

these-3-pharma-stocks-are-rallying--and-still-trade-absurdly-cheap
These 3 Pharma Stocks Are Rallying – And S...
10/02/2025 19:43:25

Health care stocks are rallying, but Pfizer, Merck and Bristol-Myers still trade below 10x forward P/E — a rare market discount.

amgen-announces-the-phase-3-vesalius-cv-clinical-trial-met-its-dual-primary-endpoints-demonstrating-that-repatha-significantly-reduced-the-risk-of-major-adverse-cardiovascular-events-in-individuals-without-a-prior-history-of-heart-attack-or-stroke
Amgen Announces The Phase 3 VESALIUS-CV Cl...
10/02/2025 13:18:29

Adding Repatha to Standard Therapy of Statins or Other LDL-C Lowering Treatments Significantly Reduces Cardiovascular Events Co...

health-care-stocks-rally-nike-beats-the-street-whats-moving-markets-wednesday
Health Care Stocks Rally, Nike Beats The S...
10/01/2025 16:56:36

Wall Street posts modest gains as shutdown begins and jobs data disappoints, but optimism around earnings and rate cuts keeps m...

marjorie-taylor-greene-loads-up-on-six-figure-treasury-bill-diversifies-portfolio-with-bitcoin-etf-tech-stocks
Marjorie Taylor Greene Loads Up On Six-Fig...
09/30/2025 07:01:26

Rep. Marjorie Taylor Greene's latest trades reveal a six-figure Treasury Bill buy, plus new stakes in tech stocks and a Bit...

amgen-expands-us-manufacturing-network-amid-new-tariff-policy
Amgen Expands US Manufacturing Network Ami...
09/26/2025 18:37:49

Just when the Trump administration announced a 100% tariff on pharmaceuticals starting in October, Amgen Inc (NASDAQ: AMGN) ann...

the-analyst-verdict-amgen-in-the-eyes-of-8-experts
The Analyst Verdict: Amgen In The Eyes Of ...
09/26/2025 14:01:22

8 analysts have shared their evaluations of Amgen (NASDAQ: AMGN) during the recent three months, expressing a mix of bullish an...

amgen-announces-650m-expansion-of-its-us-manufacturing-network-creating-hundreds-of-new-jobs
Amgen Announces $650M Expansion Of Its U.S...
09/26/2025 13:01:36

Amgen (NASDAQ: AMGN) today announced a $650 million expansion of its U.S. manufacturing network, creating hundreds of new jobs.

trumps-100-pharmaceutical-tariff-the-270-billion-manufacturing-war-that-could-reshape-your-medicine-cabinet
Trump's 100% Pharmaceutical Tariff: The $2...
09/26/2025 12:01:51

Trump’s sweeping 100% pharmaceutical tariff starting October 1 triggers massive $270 billion industry investment surge, creatin...

european-advisory-panel-recommends-two-astrazeneca-drugs-for-approval
European Advisory Panel Recommends Two Ast...
09/22/2025 18:20:56

AstraZeneca and Amgen secure CHMP support for Tezspire in nasal polyps and Koselugo in neurofibromatosis after strong Phase 3 t...

ema-backs-amgen-drug-for-rare-autoimmune-disorder
EMA Backs Amgen Drug For Rare Autoimmune D...
09/19/2025 17:17:10

European Medicines Agency's panel recommends expanding Amgen's Uplizna to treat IgG4-related disease, with trial data s...

emas-human-medicines-committee-has-recommended-extending-the-therapeutic-indication-of-uplizna--to-include-the-treatment-of-adult-patients-with-active-immunoglobulin-g4-related-disease
EMA's Human Medicines Committee Has Recomm...
09/19/2025 10:09:37

how-is-the-market-feeling-about-amgen
How Is The Market Feeling About Amgen?
09/17/2025 15:00:41

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION